Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Tuesday, March 3, 2015
China JSFDA Accepts Eisai's Application Seeking Additional Indication of Severe Alzheimer's Disease for Aricept
Monday, March 2, 2015
Eisai Launches Anticancer Agent Lenvima in the United States
Wednesday, February 25, 2015
Eisai to Establish Oral Solid Dose Production Facility at New Suzhou Plant in China
Eisai Announces Phase III Trial of Anticancer Agent Halaven in Soft Tissue Sarcoma Shows Overall Survival Benefit in Primary Endpoint
Tuesday, February 24, 2015
Additional Exploratory Analysis of Phase II Trial Suggests Anticancer Agent Lenvatinib Extends Overall Survival in Patients with Advanced Non-small Cell Lung Cancer
Thursday, February 19, 2015
Eisai Receives Approval in Japan for Fine Granule Formulation of Anti-Arrhythmic Agent Tambocor Suitable for Pediatric Patients
Wednesday, July 13, 2011
Eisai Enters into Comprehensive Chinese Marketing Agreement Concerning Breast Cancer and Parkinson's Disease Treatments
Thursday, November 18, 2010
Eisai to Provide Medecine to Help WHO Combat Lymphatic Filariasis Epidemic
Tuesday, September 7, 2010
SymBio and Eisai to Launch Symbenda(R) in Singapore for the Treatment of Low-grade Non-Hodgkin's Lymphoma and Chronic Lymphatic Leukemia
Wednesday, February 24, 2010
Eisai Launches REVOVIR(R) in the Philippines for the Treatment of Chronic Hepatitis B

Copyright © 2017 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: